All In Biotech

Drug Trial Radar · NCT07843459

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group.

Conditions

  • Healthy Volunteers
  • Alzheimer Disease
  • Amyloid
  • Plaque, Amyloid
  • Plasma

Interventions

  • LY4560736Drug

    Administered intravenously (IV)

  • LY4560736Drug

    Administered subcutaneously (SC)

  • PlaceboDrug

    Administered IV

  • PlaceboDrug

    Administered SC

  • Florbetapir F18Other

    Administered IV

  • Florbetaben F 18Other

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to 13 Weeks

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • CenExel ACT

    Anaheim, California · Recruiting

  • Irvine Clinical Research

    Irvine, California · Not yet recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, California · Recruiting

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida · Recruiting

  • K2 Medical Research - The Villages

    Lady Lake, Florida · Not yet recruiting

  • K2 Medical Research

    Maitland, Florida · Not yet recruiting

  • Charter Research

    Orlando, Florida · Not yet recruiting

  • Progressive Medical Research

    Port Orange, Florida · Not yet recruiting

  • Alzheimer's Research and Treatment Center

    Stuart, Florida · Not yet recruiting

  • K2 Medical Research - Tampa

    Tampa, Florida · Not yet recruiting

  • Charter Research

    The Villages, Florida · Not yet recruiting

  • Accel Research Sites - NeuroStudies Clinical Research Unit

    Decatur, Georgia · Not yet recruiting

  • QUEST Research Institute

    Farmington Hills, Michigan · Not yet recruiting

  • Xuanwu Hospital Capital Medical University

    Beijing, China · Not yet recruiting

  • Peking University Third Hospital

    Beijing, China · Not yet recruiting

  • Huashan Hospital, Fudan University

    Minhang District, China · Not yet recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Not yet recruiting

  • The University of Tokyo Hospital

    Bunkyō City, Japan · Not yet recruiting

  • National Center for Geriatrics and Gerontology

    Ōbu, Japan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.